Literature DB >> 32900491

CircAKT1 acts as a sponge of miR-338-3p to facilitate clear cell renal cell carcinoma progression by up-regulating CAV1.

Qingliang Zhu1, Deming Zhan2, Peng Zhu2, Yankun Chong2, Yongguo Yang3.   

Abstract

Circular RNAs (CircRNAs) have become a research focus for their important implication in tumorigenesis and cancer progression. This study intends to observe the function of circAKT1 in clear cell renal cell carcinoma (ccRCC) and its underlying molecular mechanism. In the present study, we confirmed the up-regulation of circAKT1 in ccRCC tissues and cells. High circAKT1 expression was positively associated with TNM stage, lymph node metastasis and predicted an adverse prognosis. Functionally, knockdown of circAKT1 suppressed cell proliferation, colony formation, migration, invasion and EMT in vitro. Mechanistic analysis uncovered that circAKT1 could act as a sponge for miR-338-3p to prevent the degradation of caveolin-1 (CAV1). Interestingly, the anti-neoplastic effect of circAKT1 knockdown on ccRCC was abated due to miR-338-3p down-regulation or CAV1 overexpression. To summarize, circAKT1 facilitated ccRCC progression at least partly by sequestering miR-338-3p to up-regulate CAV1 expression. Our findings raised the possibility of exploiting circAKT1 as a potential prognostic biomarker and therapeutic target in ccRCC.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Caveolin-1; Clear cell renal cell carcinoma; circAKT1; miR-338–3p

Year:  2020        PMID: 32900491     DOI: 10.1016/j.bbrc.2020.08.081

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  The functions, oncogenic roles, and clinical significance of circular RNAs in renal cell carcinoma.

Authors:  Hui Huang; Tao Chen; Fei Li; Dan Jin; Chuan Li; Yongbo Yang; Xuyang Liu; Dongmiao Wang; Jiehui Di
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.064

2.  Circular RNAs as Prognostic Biomarkers in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Dan Liao; Qiu Lin; Huan Xiao; Fenglian Zhang; Qin Han
Journal:  Front Genet       Date:  2022-06-08       Impact factor: 4.772

Review 3.  Molecular interactions of miR-338 during tumor progression and metastasis.

Authors:  Meysam Moghbeli
Journal:  Cell Mol Biol Lett       Date:  2021-04-07       Impact factor: 5.787

Review 4.  CircRNAs as Novel Biomarkers and Therapeutic Targets in Renal Cell Carcinoma.

Authors:  Yuxia Zhou; Cheng Li; Zhenping Wang; Shuangfeng Tan; Yiqi Liu; Hu Zhang; Xuefeng Li
Journal:  Front Mol Biosci       Date:  2022-02-11

5.  Systematic Review With Meta-Analysis: Diagnostic, Prognostic and Clinicopathological Significance of CircRNA Expression in Renal Cancer.

Authors:  Wujun Wang; Shengfang Xie; Dongping Yuan; Dandan He; Liming Fang; Fengfeng Ge
Journal:  Front Oncol       Date:  2022-01-28       Impact factor: 6.244

6.  SPRR3, a novel miR-338-3p target, regulates the malignant progression of clear cell renal cell carcinoma in vitro via the PI3K/Akt signaling pathway.

Authors:  Man Wu; Qiaoyan Guo; Xianjun Liu; Linlin Wu
Journal:  Exp Ther Med       Date:  2022-03-08       Impact factor: 2.447

Review 7.  Circular RNAs as prognostic and diagnostic biomarkers in renal cell carcinoma.

Authors:  Sina Rashedi; Mahta Mardani; Ali Rafati; Mohammad Mahdi Khavandi; Fatemeh Mohammadi; Salar Javanshir; Rojin Sarallah; Mahsa Dolatshahi; Mohammadmahdi Sabahi; Sina Azadnajafabad; Hamed Tavolinejad; Nima Rezaei
Journal:  J Clin Lab Anal       Date:  2022-08-21       Impact factor: 3.124

Review 8.  Caveolin-1 Regulates Cellular Metabolism: A Potential Therapeutic Target in Kidney Disease.

Authors:  Shilu Luo; Ming Yang; Hao Zhao; Yachun Han; Na Jiang; Jinfei Yang; Wei Chen; Chenrui Li; Yan Liu; Chanyue Zhao; Lin Sun
Journal:  Front Pharmacol       Date:  2021-12-10       Impact factor: 5.810

9.  Construction of circRNA-based ceRNA network and its prognosis-associated subnet of clear cell renal cell carcinoma.

Authors:  Yuwei Zhang; Yuchen Zhang; Yangkun Feng; Nan Zhang; Saisai Chen; Chaoqun Gu; Lei Hu; Jiayi Sheng; Bin Xu; Ninghan Feng
Journal:  Cancer Med       Date:  2021-09-27       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.